Sperogenix Therapeutics of Beijing in-licensed a CNS drug from Barcelona 's Minoryx Therapeutics in a $78 million agreement. Sperogenix will own China rights to leriglitazone, a brain penetrating disease-modifying PPAR-y agonist. The candidate is a proposed treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening disease. Sperogenix was formed in 2019 with backing from Lilly Asia Ventures and Morningside Venture Capital to bring later clinical stage and commercial stage treatments for rare diseases to China . More details... Share this with colleagues: // //